Grifols (GIFLF) Treasury Shares (2009 - 2025)
Grifols' (GIFLF) quarterly Treasury Shares came in at -$152.5 million in Q4 2025, down 5.7% on a YoY basis from -$161.7 million in Q4 2024, and down 5.7% quarter-over-quarter from -$144.3 million in Q4 2024.
Analysis
Grifols (GIFLF) Treasury Shares (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Treasury Shares for 17 consecutive years, with -$152.5 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Treasury Shares fell 5.7% year-over-year to -$152.5 million; the trailing twelve-month figure through Dec 2025 stood at -$152.5 million (down 5.7% YoY), and the FY2025 full-year result was -$148.0 million, down 2.6% from the prior year.
- Treasury Shares eased to -$152.5 million in Q4 2025 per GIFLF's latest filing, from -$144.3 million in the prior quarter.
- Across five years, Treasury Shares topped out at -$144.3 million in Q4 2024 and bottomed at -$187.8 million in Q4 2021.
- Historically, Treasury Shares has averaged -$162.9 million across 5 years, with a median of -$164.3 million in 2023.
- The sharpest annual moves came in 2021 and 2024: Treasury Shares plunged 260.21% in 2021, then gained 12.22% in 2024.
- Over 5 years, Treasury Shares stood at -$187.8 million in 2021, then rose by 11.88% to -$165.5 million in 2022, then increased by 0.7% to -$164.3 million in 2023, then rose by 12.22% to -$144.3 million in 2024, then retreated by 5.7% to -$152.5 million in 2025.
- According to Business Quant data, Treasury Shares over the past three periods registered -$152.5 million, -$144.3 million, and -$164.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 36.40 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -23.80 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | -152.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -152.49 Mn |
| Dec 31, 2025 | -152.49 Mn |
| Dec 31, 2024 | -144.26 Mn |
| Dec 31, 2024 | -144.26 Mn |
| Dec 31, 2023 | -164.35 Mn |
| Dec 31, 2023 | -164.35 Mn |
| Dec 31, 2022 | -165.50 Mn |
| Dec 31, 2022 | -165.50 Mn |
| Dec 31, 2021 | -187.83 Mn |
| Dec 31, 2021 | -187.83 Mn |
| Dec 31, 2020 | -52.14 Mn |
| Dec 31, 2020 | -52.14 Mn |
| Sep 30, 2020 | -51.08 Mn |
| Sep 30, 2020 | -51.08 Mn |
| Mar 31, 2020 | -54.21 Mn |
| Mar 31, 2020 | -54.21 Mn |
| Dec 31, 2019 | -54.88 Mn |
| Dec 31, 2019 | -54.88 Mn |
| Sep 30, 2019 | -55.17 Mn |
| Sep 30, 2019 | -55.17 Mn |